NCT07539753 2026-04-20
Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
Clinical Trials
5 trialsNCT07307287 2025-12-29
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07179939 2025-09-18
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
Phase 2 Not yet recruiting
NCT06556862 2025-08-13
Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
Beijing 302 Hospital
Phase 2 Not yet recruiting
NCT07101159 2025-08-03
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
Fujian Cancer Hospital
Phase 2 Not yet recruiting